Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in Stock

Posted by Brian Himes on Sep 12th, 2026

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak Azamian sold 10,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $90.56, for a total value of $905,600.00. Following the transaction, the chief executive officer directly owned 827,991 shares of the company’s stock, valued at approximately $74,982,864.96. This represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $79.31 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.17 and a current ratio of 3.20. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $91.53. The firm has a market capitalization of $3.48 billion, a PE ratio of -72.76 and a beta of 0.54. The stock’s 50-day simple moving average is $68.12 and its 200-day simple moving average is $66.64.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The company had revenue of $173.91 million for the quarter, compared to analysts’ expectations of $169.65 million. As a group, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.4 EPS for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Rockefeller Capital Management L.P. grew its holdings in shares of Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares during the last quarter. Parallel Advisors LLC raised its stake in Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after acquiring an additional 291 shares during the last quarter. State of Wisconsin Investment Board raised its stake in Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after acquiring an additional 332 shares during the last quarter. Federated Hermes Inc. lifted its position in Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after acquiring an additional 339 shares during the period. Finally, Valeo Financial Advisors LLC grew its stake in shares of Tarsus Pharmaceuticals by 11.1% in the 4th quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after purchasing an additional 392 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on TARS. HC Wainwright reiterated a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Guggenheim decreased their target price on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Finally, Jefferies Financial Group boosted their price objective on Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $92.57.

View Our Latest Report on TARS

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company’s lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites.

XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms.